Close Menu

Cancer

The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.

Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.

A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.

The Cambridge, Massachusetts-based company recently reported positive interim results for the RET-targeting agent from the Phase I/II ARROW study.

In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations. 

Bolt's lead candidate, BDC-1001, is an immune-stimulating antibody conjugate currently being studied in a Phase I clinical trial in HER2-expressing solid tumors.

Jul
16

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.